It is increasingly evident from a growing number of studies that aberrant expression and activity of SCD1 are associated with an elevated risk of a range of metabolic disorders, including obesity, MASLD, and type 2 diabetes mellitus [63,64,65]. Here, SCD is linked to metabolic dysfunction-associated steatotic liver disease.